FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
Here's a development that aims to keep your blood pressure in check. Literally!
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Subscribe To Our Newsletter & Stay Updated